Modulation of Temozolomide Dose Differentially Affects T cell Response to Immune Checkpoint Inhibition

A presentation at the 2019 American Association of Neurological Surgeons Annual Scientific Meeting

Article ID: 711288

Released: 15-Apr-2019 7:00 PM EDT

Source Newsroom: American Association of Neurological Surgeons (AANS)

Newswise — SAN DIEGO (April 15, 2019) — Winner of the Preuss Research Award, Maryam Rahman, MD, FAANS, presented her research, Modulation of Temozolomide Dose Differentially Affects T cell Response to Immune Checkpoint Inhibition, during the 2019 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.

Temozolomide has been shown to have both synergistic and negative effects on immune response to different immunotherapy treatment platforms. Researchers aimed to determine the immune modulatory effects of temozolomide that would impact response to immune checkpoint inhibition in the treatment of experimental glioblastoma (GBM).

The study found that the peripheral and intratumoral immune microenvironments are distinctively affected by dose modulation of temozolomide impacting response to immune checkpoint inhibition in GBM. These results demonstrate the importance of thoughtfully modulating host immunity with chemotherapy, when combining with immunotherapy.

Author Block: Maryam Rahman, MD, FAANS (Gainesville, Fla.); Aida Karachi, DVM; Changlin Yang, MD, PhD; Farhad Dastmalchi, DVM; Elias Sayour, MD, PhD; Jianping Huang, MD, PhD; Duane Mitchell, MD, PhD

Disclosure: The author reported no conflicts of interest.

Media Representatives: The 2019 AANS Annual Scientific Meeting website’s press section includes releases on highlighted scientific research, AANS officers and award winners and other relevant information about the 2019 program. Releases will be posted on the 2019 AANS Annual Scientific Meeting website. If you have interest in a topic related to neurosurgery or would like to interview a neurosurgeon — either onsite or via telephone — during or after the event, please contact Alice Kelsey, AANS associate executive director, via email at aik@aans.org.

About the 2019 AANS Annual Scientific Meeting
Attended by neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants, allied health professionals and other medical professionals, the AANS Annual Scientific Meeting is the largest gathering of neurosurgeons in the nation, with an emphasis on the field’s latest research and technological advances. The scientific presentations accepted for the 2019 event will represent cutting-edge examples of the incredible developments taking place within the field of neurosurgery. Find additional information about the 2019 AANS Annual Scientific Meeting and the meeting program here.

About the AANS
Founded in 1931 as the Harvey Cushing Society, the American Association of Neurological Surgeons (AANS) is a scientific and educational association with more than 11,500 members worldwide. The AANS promotes the highest quality of patient care and advances the specialty of neurological surgery. Fellows of the AANS are board-certified by the American Board of Neurological Surgery, the Royal College of Physicians and Surgeons of Canada or the Mexican Council of Neurological Surgery, A.C. Neurosurgery is the medical specialty concerned with the prevention, diagnosis, treatment and rehabilitation of disorders that affect the spinal column, spinal cord, brain, nervous system and peripheral nerves.

For more information, visit www.AANS.org.

  • share-facebook-Modulation of Temozolomide Dose Differentially Affects T cell Response to Immune Checkpoint Inhibition
  • share-twitter-Modulation of Temozolomide Dose Differentially Affects T cell Response to Immune Checkpoint Inhibition

Comment/Share

step 2
Chat now!